Passage of American Rescue Plan Act of 2021 Could Mean Larger Medicaid Drug Rebate Program Rebates for Pharmaceutical Manufacturers

Arent Fox
Contact

Arent Fox

The American Rescue Plan Act of 2021, signed into law by President Biden on March 11, 2021, is a $1.9 trillion aid package that provides assistance to businesses and individuals experiencing financial hardship due to COVID-19.
 

But buried in the bill is Section 9816 which sunsets the cap on Medicaid Drug Rebate Program rebates at Average Manufacturer Price (AMP) beginning January 1, 2024.  This means that pharmaceutical manufacturers could pay Medicaid Drug Rebate Program rebates greater than AMP for Medicaid utilization in the first quarter of 2024 and after. This most likely would occur in the event AMP rises faster than inflation and could lead manufacturers to discontinue certain covered outpatient drug products or simply cease participating in Medicaid entirely.     

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Arent Fox | Attorney Advertising

Written by:

Arent Fox
Contact
more
less

Arent Fox on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.